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Structured Abstract 
Study Design: This study investigates the effect of Vancomycin and Gentamicin 
antibiotics on primary human osteoblasts. Osteoblasts were incubated with 
vancomycin, gentamicin or with Povidone-Iodine (PVI), at concentrations advocated 
for wound irrigation.  Osteoblast proliferation, metabolic function and bone 
mineralisation were measured. 
 
Objective: To model Gentamicin and Vancomycin wound irrigation in vitro and 
examine the effect on osteoblast viability and cellular function in comparison to 
0.35% PVI. 
 
Summary of Background Data:  Vancomycin, Gentamicin and dilute PVI are 
employed as wound irrigants in spinal surgery to reduce infection.  However, we 
have recently demonstrated that 0.35% PVI has a detrimental effect on osteoblast 
cellular function and bone mineralisation. Studies to determine the effects of 
antibiotic wound irrigation solutions on osteoblasts and bone mineralisation are 
therefore warranted. 
 
Methods: Primary human osteoblasts were exposed for 20 min to either PBS control, 
Vancomycin (35 mM or 3.5 mM), Gentamicin (34 mM or 3.4 mM) or 0.35% PVI for 3 
min.  Cellular proliferation was measured over 7 days by MTS assay.  Osteoblast 
metabolic function was determined using a Seahorse XFe24 Bioanalyzer.  
Mineralised bone nodules were quantified using Alizarin red. 
 
Structured Abstract (300 words)
 Vancomycin, Gentamicin and osteoblast proliferation 
 
Results:  At concentrations advocated for wound irrigation, both Gentamicin (3.4 
mM) and Vancomycin (3.5 mM) induced a transient 15-20% reduction in osteoblast 
proliferation, which returned to control values within 72 h.  This was in marked 
contrast to the effect of 0.35% PVI which resulted in a sustained reduction in 
osteoblast proliferation of between 40-50% over 7 days.  Neither Gentamicin nor 
Vancomycin at concentrations up to 10x clinical dose had any effect on osteoblast 
oxygen consumption rate, or significantly affected mineralised bone nodule 
formation.    
 
Conclusion:  Vancomycin and Gentamicin solutions, at concentrations advocated for 
intrawound application in spinal surgery have a small but transient effect on 
osteoblast proliferation, and no effect on either osteoblast metabolic function or bone 
nodule mineralisation.  
 
Key Words 
Adolescent idiopathic scoliosis; osteoblasts; vancomycin; gentamicin; povidone 
iodine; PVI; bone; wound irrigation; antibiotics; bone mineralisation; cell proliferation, 
cell metabolism, surgical site infections 
 
Level of Evidence: N/A 
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Key Points 
 Acute exposure to clinically employed concentrations of Gentamicin and 
Vancomycin (3.4 mM and 3.5 mM respectively) induces a small but transient 
reduction in the proliferation of osteoblasts, in contrast to 0.35% PVI which 
induces a marked and sustained reduction in osteoblast proliferation 
 Gentamicin or Vancomycin up to 10x clinical dose did not affect osteoblast 
metabolic capacity (OCR), or effect bone nodule mineralisation, in contrast to 
0.35% PVI. 
 
Key Points (3-5 main points of the article)
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Mini abstract 
This study modelled the effect of using Gentamicin and Vancomycin antibiotics 
during spinal surgery on human primary osteoblast cells.  Osteoblasts treated with 
clinically employed concentrations of Gentamicin or Vancomycin, exhibited a small 
but transient reduction in proliferation, and no change in metabolic capacity or ability 
to form mineralised bone. 
Mini Abstract (50 words)
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Introduction 1 
Surgical site infections (SSIs) following spinal surgery are a serious complication, 2 
which negatively impact on patient outcomes and can be fatal.  Such incidences can 3 
require additional operations involving antibiotic irrigation of the wound and 4 
debridement 1,2, and in certain cases, the spinal implants must be removed: an 5 
expenditure of both time and healthcare resources 3.  Indeed, infection-related costs 6 
have been reported to be an additional $30,000 per patient 4.  7 
 8 
In order to combat infection, several prophylactic measures are in use 5. Peri-9 
operative broad spectrum antibiotic usage is standard in orthopaedic surgery and 10 
does significantly reduce risk of infection 6.  However, in addition, in order to reduce 11 
rates further, and due to the rise of Methicillin-Resistant Staphylococcus Aureus 12 
(MRSA) 7, intrawound broad-spectrum antibiotics including Vancomycin and 13 
Gentamicin 8,9,10 may be applied.  Unfortunately, there are very few 14 
recommendations from historical literature with regards to the use of antibiotics to 15 
combat SSI rates in spinal surgery, and thus clinical practice varies considerably.    16 
 17 
In a systematic review, particularly high SSI rates (3.5% to 8.5%) were noted in 18 
spinal surgery in paediatric patients with cerebral palsy, spina bifida, patients with 19 
urinary tract infections, incontinence obesity and those patients undergoing pelvic 20 
fixation procedures 11.  This review was the basis for constructing the Best Practice 21 
Guidelines, where the intrawound application of Vancomycin is specifically 22 
recommended 12 for spinal surgery in paediatric patients.  Several studies, including 23 
large randomised control trials, have provided evidence that administration of 24 
intrawound Vancomycin is safe 13 and efficacious in reducing the incidence of SSIs, 25 
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when compared to prophylactic antibiotics alone 14,15,16,17,18.  Similarly, intrawound 26 
application of Gentamicin has also been shown to reduce infection rates spinal 27 
surgery in children with cerebral palsy, with a reduction from 15.2% to 3.9% 28 
observed 19.   29 
 30 
Some spinal units have reported that wound irrigation with a solution of Povodine-31 
Iodine (PVI;Betadine) 20,21 is safe and efficacious at reducing SSI rates in spinal 32 
surgery.  Furthermore, a protocol which combined PVI wound irrigation with 33 
intrawound Vancomycin powder was recently advocated as being highly effective at 34 
reducing SSI rates in spinal surgery, with a reduction of 50% reported 22.  However, 35 
we have recently reported that exposure of human osteoblasts to 0.35% PVI (the 36 
concentration advocated for wound irrigation), is highly cytotoxic to osteoblasts, with 37 
a marked and sustained reduction in osteoblast cellular proliferation and inhibition of 38 
mineralised bone formation 23.  This particular study highlighted the importance for 39 
spinal units to evaluate not only the SSI antibacterial efficacy of such intrawound 40 
reagents, but to also to consider the effect of these reagents on the cellular 41 
osteoblast function.        42 
 43 
Critically, no studies have reported the effects of Vancomycin or Gentamicin 44 
antibiotics on human primary osteoblast mineralised bone formation.  Neither has 45 
their effect on osteoblast proliferation been reported following an in vitro protocol that 46 
mimics the transient high concentrations of antibiotics in the surgical wound following 47 
intrawound application.  Given that the goal of many spinal surgeries is to establish 48 
solid bone union, it is important to know whether these reagents, like PVI, may 49 
impair bone healing since this may help guide clinical practice.  The aim of this study 50 
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was therefore to model in vitro the effect of Vancomycin and Gentamicin antibiotic 51 
solutions on osteoblast proliferation, osteoblast metabolism and mineralised bone 52 
nodule formation.   53 
54 
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METHODS 55 
3.1 Cell culture 56 
Ethical approval was granted by the United Kingdom (UK) National Research Ethics 57 
Service (National Health Authority, reference NRES 14-ES-1044), and institutionally 58 
approved and sponsored by the University of Birmingham as required under the UK 59 
Research Governance Framework. Study participants were provided in advance with 60 
a participant information sheet, and a participant consent form.   61 
 62 
Following patient’s written consent, the femoral head was collected from a female 63 
patient (aged 62 years) undergoing total joint replacement surgery for hip 64 
osteoarthritis.  The articular cartilage was removed from the femoral head and the 65 
subchondral bone cut into small chips. The bone chips were then washed thoroughly 66 
in serum-free primary osteoblast media to remove any excess blood, connective or 67 
adipose tissue and then incubated in differentiation media  (10% FCS, penicillin 68 
(100units/ml), streptomycin (100µg/ml), L-glutamine (2mM), β-glycerophosphate 69 
(2mM), Ascorbic acid (50µg/ml) and Dexamethasone (10nM)) in a culture flask at 70 
37°C (5% CO2). Differentiation media was replaced with fresh media 2x per week, 71 
and the bone chips removed upon the appearance of osteoblast cells. Primary 72 
human osteoblast cells were cultured in differentiation media.  73 
 74 
The experimental concentrations of Vancomycin and Gentamicin utilised for this 75 
study were based on the serial observation of average wound drain outputs following 76 
turning patients from the table. From this it was estimated that an average scoliosis 77 
wound held approximately 200 ml of fluid.  Furthermore, it was considered that the 78 
majority of Vancomycin and Gentamicin antibiotic would be washed out after closure 79 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 Vancomycin, Gentamicin and osteoblast proliferation 
5 
 
following opening of the drain after 20 min. Therefore an experimental concentration 80 
of 1g of Vancomycin or Gentamicin in 200ml of PBS solution (equating to 3.5 mM 81 
and 3.4 mM respectively) exposed for 20 min would best mimic the clinical 82 
concentration and exposure time.  Higher concentrations at 10X the estimated 83 
clinical concentration was utilised for the second experimental setting, equating to 35 84 
mM and 34 mM for Vancomycin and Gentamicin respectively.  The experimental 85 
concentration of PVI utilised was 0.35%, which has previously been clinically 86 
advocated.  Cells were exposed for 3 min with 0.35% PVI, before washing with PBS 87 
in order to mimic the clinical saline washout procedure.  88 
 89 
 90 
3.3  Osteoblast proliferation assay 91 
Primary human osteoblasts were seeded at 6x103 cells per well in a 96 well plate.  At 92 
confluency, osteoblasts were stimulated with either Vancomycin (3.5 mM or 35 mM), 93 
or Gentamicin (3.4 mM or 34 mM) for 20 min, or with 0.35% PVI for 3 min.  All wells 94 
were then aspirated, washed 5x with PBS and then filled into osteoblast 95 
differentiation media. After 0, 24, 48, 72 and 144 h incubation at 33°C, an MTS (Cell 96 
Titer Aqueous One Solution Cell Proliferation Assay, Promega) assay was 97 
performed as per manufacturer’s instructions as a measure of osteoblast 98 
proliferation.   99 
 100 
3.4  Osteoblast metabolic function 101 
Primary human osteoblasts were plated at 6x103 cells per well in a XFe 24 Cell 102 
Culture Microplate (Seahorse Bioscience, USA). At confluency, the cells were 103 
stimulated, washed and incubated exactly as in the proliferation assay and then 104 
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placed back into media. After 24 h incubation at 33°C, XF Assay medium (XF base 105 
medium with 2mM GlutaMAX™) was then added to the plate and incubated at 33°C 106 
for 1 h. Osteoblast oxygen consumption rate (OCR) was determined using a XFe 107 
Extracellular Flux Analyzer (Seahorse Bioscience, USA), as a measure of osteoblast 108 
metabolic function.    109 
 110 
3.7 Osteoblast bone nodule formation and mineralization assay 111 
Primary human osteoblasts were seeded at 6x103 cells per well in an 96-well plate 112 
and stimulated, incubated and washed as previously described before being cultured 113 
in differentiation media.  After 28 days, cells were stained with Alizarin red solution in 114 
order to quantify the degree of mineralisation following the formation of bone 115 
nodules. Briefly, cells were incubated in 0.5% Alizarin Red staining solution (Sigma-116 
Aldrich, UK) in 1% ammonia solution at pH 4.5 for 10min at room temperature and 117 
washed with PBS to remove excess stain.  Cells were then incubated in 10% cetyl 118 
pyridinium chloride (Sigma-Aldrich, UK) for 10 min at room temperature. The 119 
supernatant was collected from each well and diluted 1:10 with the 10% cetyl 120 
pyridinium chloride and read at OD550nm on a SpectraMAX Microplate Reader 121 
(Molecular Devices, USA). 122 
 123 
3.8 Statistical Analysis  124 
All statistical analyses were carried out using SPSS. Unless otherwise stated, all 125 
data within figures represents Mean ±SEM and were assessed by a two-way 126 
analysis of variance (ANOVA) with a Bonferronni post-hoc test conducted where 127 
appropriate.  Significance was accepted as P<0.05.  128 
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Results 130 
3.1 The effect of acute exposure to Vancomycin and Gentamicin antibiotics on 131 
osteoblast proliferative activity 132 
Relative to normal osteoblast proliferation (PBS control), 20 min exposure of human 133 
osteoblasts to Gentamicin at the clinical concentration of 3.4 mM resulted in a 134 
significant reduction in osteoblast proliferation of 12% after 24h (P<0.05), and 22% 135 
after 48 h (P<0.01).  However, at 3 days, osteoblast proliferation had returned to 136 
control levels.  At 10x clinical dose of 34 mM Gentamicin, a similar reduction in 137 
osteoblast proliferation was observed, peaking at a 27% reduction after 48 h 138 
(P<0.001).  However, osteoblasts exposed to 34 mM Gentamicin exhibited a more 139 
sustained reduction in osteoblast proliferation, with a significant 14% reduction 140 
(P<0.05) observed at 7 days post exposure (Figure 1A). 141 
 142 
Vancomycin at 3.5 mM had no significant effect on osteoblast proliferation at 24 h, 143 
but there was a small 15% reduction in proliferation relative to control at 48 h.  144 
However, proliferation levels returned to control levels at 3 days post exposure.  145 
Similar to our findings with Gentamicin, the 10x clinical dose of 35 mM Vancomycin 146 
induced a more pronounced inhibition of osteoblast proliferation of between 18-24% 147 
and this effect was sustained up to 7 days post exposure (Figure 1B).  148 
 149 
In contrast, osteoblasts exposed to 0.35% PVI for 3 min exhibited a much greater 150 
reduction in proliferation of between 40-50% which was sustained between 24 h and 151 
7 days (P<0.001) (Figure 1A & 1B).  152 
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3.2 Acute exposure to Vancomycin and Gentamicin antibiotics does not affect 153 
human osteoblast basal metabolic function. 154 
Given these differential findings between the effects of antibiotic reagents and PVI 155 
on osteoblast proliferation, we next compared their effects on osteoblast metabolic 156 
function.  As we have previously reported, osteoblasts exposed for 3 min to 0.35% 157 
exhibit a significant 94% reduction (P<0.001) in basal oxygen consumption rate 158 
(OCR) 23.  However, in contrast neither Gentamicin nor Vancomycin, at either clinical 159 
dose or 10x clinical dose, elicited any significant reduction in osteoblast OCR.  In 160 
osteoblasts that had been exposed 35 mM Vancomycin, OCR was on average lower 161 
than PBS control, although this did no reach statistical significance (Figure 2A & 2B). 162 
 163 
3.4 Acute exposure of human osteoblasts to Vancomycin and Gentamicin does 164 
not inhibit the formation of mineralised bone 165 
We next examined whether acute 20 min exposure of human osteoblasts to 166 
Vancomycin or Gentamicin had a chronic effect on their ability to form mineralised 167 
bone nodules.  Following exposure to Vancomycin, Gentamicin or PBS control, 168 
confluent osteoblasts were kept in culture for a further 2 weeks before mineralised 169 
bone nodules were stained and quantified using Alizarin red (Figure 3A).  Although, 170 
on average the degree of bone mineralisation was lower in osteoblasts which had 171 
been exposed to antibiotics, there was no significant reduction observed with either 172 
Gentamicin or Vancomycin at either clinical dose or 10x clinical dose (Figure 3B and 173 
3C).        174 
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Discussion 175 
This study shows that, at concentrations advocated for intrawound application, 176 
Vancomycin (3.5 mM) and Gentamicin (3.4 mM) elicit a small (15-20% reduction) in 177 
osteoblast proliferation.  Critically however, this effect was transient, with osteoblast 178 
proliferation returning to normal within 72 h post-exposure.  Furthermore, there was 179 
no impact on either osteoblast metabolic capacity or the ability of osteoblasts to form 180 
mineralised bone at these concentrations.  These findings were in stark contrast to 181 
our findings with PVI, where the detrimental effects on osteoblast proliferation were 182 
significantly greater (40%-50% inhibition) and were sustained for up to 7 days.   183 
 184 
These findings are clinically important since there are clear advantages to surgical 185 
intrawound application of antibiotics compared to intravenous administration.  Firstly, 186 
in the Best Practice Guidelines, intrawound application of Vancomycin is favoured 187 
over intravenous delivery due to concerns about its potential systemic toxicity 12.  188 
Critically, although intrawound vancomycin is absorbed systemically, the systemic 189 
levels are low 14, thus higher concentrations can be applied where required without 190 
concerns for systemic toxicity 14. Furthermore, wounds are complicated by seroma, 191 
haematomas and devitalised tissue.  Such tissues present barriers, which systemic 192 
prophylactic antibiotics poorly penetrate 24.  Indeed, in a rabbit surgical wound 193 
infection model, intrawound Vancomycin was significantly more effective at 194 
eliminating SSIs than intravenous cefazolin alone 25.   195 
 196 
Despite our data showing that Vancomycin (at 3.5 mM) and Gentamicin (at 3.4 mM) 197 
elicit only a small and transient effect on osteoblast proliferation, a previous study 198 
using the human MG-63 osteosarcoma cell line 26 found that Vancomycin at 1000 199 
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ug/ml (equivalent to 0.68 mM) had no effect on cell viability, but was toxic at a 200 
concentration of 10,000 ug/ml (6.8 mM).  Similarly, Gentamicin at concentrations up 201 
to 1000 ug/ml (2 mM) have previously been reported to reduce alkaline phosphatase 202 
activity in osteoblast-like cells from cancellous hip bone 27.  However, it is important 203 
to note that firstly in the study by Edin et al. 26 the utilised cells were not primary cells 204 
and, although classed as “osteoblast-like”, their proliferation rate and alkaline 205 
phosphatase activity is not considered very representative of bone 28.  Secondly, in 206 
the study by Edin et al. 26 the cells were exposed to Vancomycin for 24-72 hours, 207 
and in the study by Isefuku et al. 27 cells were exposed to Gentamicin for 4 days.  208 
Such lengthy in vitro protocols are likely to poorly mimic the transient high 209 
concentration of Vancomycin within the surgical site following intrawound clinical 210 
application 14.  Our in vitro data supports clinical observations which report no 211 
indications of bone growth problems in patients where bone allografts have been 212 
supplemented with Vancomycin in hip revision surgery 29. 213 
 214 
Importantly, despite the Best Practice Publication 12  not including PVI irrigation 215 
amongst the recommendations, the use of PVI either alone or in combination with 216 
intrawound antibiotics is still being advocated by several spinal units 22,20,21.  217 
Furthermore, there are currently no clinical studies which have demonstrated greater 218 
gains in reducing SSI rates using PVI irrigation compared to using intrawound 219 
antibiotics.   Therefore, given the clear differential effects we report here on 220 
osteoblast viability, it would appear pertinent for clinicians to favour the practice of 221 
intrawound Vancomycin or Gentamicin application over 0.35% PVI wound irrigation.  222 
Furthermore, although the combination of Vancomycin intrawound with PVI wound 223 
irrigation was recently reported to provide a commendable 50% reduction in SSI 224 
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rates in spinal surgery 22, our data suggests this practice should be approached 225 
cautiously.  Such caution may be particularly warranted for paediatric patients 226 
undergoing long fusion surgical procedures (4 levels of more), with high non-union 227 
rates 30,31,32, where any gains in reducing SSI rates with PVI alone (or in combination 228 
with Vancomycin) may be offset by impaired bone healing.   229 
 230 
 It is important to stress the limitations of this study.  It is an in vitro study, and 231 
although the human osteoblasts are primary cells they do not originate from spinal 232 
bone tissue.  Furthermore, such in vitro studies cannot fully replicate the complexity 233 
of the in vivo environment, where for example pluripotent stem cells may migrate to 234 
the site of surgery and aid bone healing and fusion.  Nevertheless, our data suggests 235 
a clear differential between the effects of Vancomycin and Gentamicin antibiotics 236 
compared to PVI on osteoblast proliferation and function. 237 
 238 
In summary, at concentrations advocated for the reduction of SSIs in spinal surgery 239 
Vancomycin and Gentamicin had no sustained effect on osteoblast proliferation, or 240 
the formation of mineralised bone.  We suggest therefore that in contrast to PVI 241 
wound irrigation, the intrawound application of the either Vancomycin or Gentamicin 242 
in spinal surgery would be unlikely to impair bone healing.  243 
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Abbreviations 244 
 245 
PVI   Povidone-Iodine 246 
PBS   Phosphate buffered saline 247 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-248 
sulfophenyl)-2H-tetrazolium, inner salt 249 
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Figure legends 
 
Figure 1.  The effect of acute exposure to antibacterial intrawound reagents on 
primary human osteoblast proliferation.  (A) Osteoblasts were stimulated for 20 
min with either PBS control, Gentamicin (34 mM or 3.4 mM) or stimulated for 3 min 
with 0.35% PVI.  (B) Osteoblasts were stimulated for 20 min with either PBS control, 
Vancomycin (35 mM or 3.5 mM) or stimulated for 3 min with 0.35% PVI.  Osteoblast 
proliferation was measured by MTS assay (absorbance at 490 nm) at time 0, day 1, 
3, 4 and day 7.  Bars represent mean ± SEM (n=3), with *=P<0.05, †=P<0.01, 
‡=P<0.001, representing values significantly different to PBS control. 
 
Figure 2.  Metabolic activity of primary human osteoblast following acute 
exposure to antibiotic intrawound reagents.  (A)  Oxygen consumption rate 
(OCR) of osteoblasts 24 h after 20 min exposure to either Gentamicin (34 mM or 3.4 
mM) or 3 min exposure to 0.35% PVI.  (B) OCR of osteoblasts after 20 min exposure 
to either Vancomycin (35 mM or 3.5 mM) or 3 min exposure to 0.35% PVI.  Bars 
represent mean ± SEM (n=3), with ‡=P<0.001, representing values significantly 
different to PBS control. 
 
Figure 3.  Primary human osteoblast mineralisation following acute exposure 
to antibiotic intrawound reagents.  (A) Representative microscopic images (x20 
magnification) of phase contrast of primary human osteoblasts, and Alizarin red 
stained mineralised bony nodules after 28 days post fully confluent. Primary human 
osteoblasts were cultured out bone chips in differentiation media.   (B)  
Quantification by absorptiometry (at 490 nm) of Alizarin red stained mineralised bone 
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nodules in osteoblast 14 days after acute 20 min exposure to either Gentamicin (34 
mM or 3.4 mM), Vancomycin (35 mM or 3.5 mM) or PBS media control.  Bars 
represent mean ± SEM (n=3).  (C) Representative microscopic images showing 
images of Alizarin red stained mineralised bone nodules 14 days after exposure to 
Gentamicin and Vancomycin antibiotics.  
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